OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies.
General Information
OPTIMER PHARMAC
10110 Sorrento Valley Road Suite C
San Diego, CA 92121
Phone: 858-909-0736
Fax: 858-909-0737
Web: www.optimerpharma.com
Email: None
Sponsored Links 
N/A